# US 2025/0027049 A1 · Islet-like organoid expressing monstim1 in which insulin secretion is regulated by optical stimulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0027049 A1
- Document ID: US20250027049A1
- Status: Published application
- Kind: A1
- Application number: 18/715,678
- Filed: 2022-11-29
- Published: 2025-01-23
- Earliest claimed: 2021-12-02
- Assignees: Korea Advanced Institute of Science and Technology
- Applicants: Korea Advanced Institute of Science and Technology
- Inventors: Yong Mahn Han; Wondo Heo; Ji Eun Choi; Jinsu Lee; Eun Ji Shin
- Web page: https://patentgrep.com/patent/US20250027049A1

## CPC

- C12N 5/0677: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- A61F 2/02: Prostheses implantable into the body
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C12N 5/06: {Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}
- C12N 5/0676: {Pancreatic cells}
- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2529/10: Stimulation by light
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an islet-like organoid in which insulin secretion can be optically regulated by differentiating, into pancreatic islets, human pluripotent stem cells (monSTIM1-hPSC) obtained by knocking-in monSTIM1, which is an inducer of Ca2+ concentration increase (Ca2+ transient), into the AAVS1 locus of the stem cells. Since it has been confirmed in vitro and in the body of a diabetic mouse model that the islet-like organoid of the present invention can secrete insulin through an intracellular calcium influx increased by light irradiation, the islet-like organoid can be effectively used in the treatment of diabetic patients.

## Claims

### Claim 1

An islet-like organoid expressing monSTIM1 in which insulin secretion is regulated by light irradiation.

### Claim 2 (depends on 1)

The islet-like organoid expressing monSTIM1 according to claim 1, wherein the light is blue light having a wavelength of 470 to 500 nm.

### Claim 3 (depends on 1)

The islet-like organoid expressing monSTIM1 according to claim 1, wherein the monSTIM1 is activated by light irradiation to increase intracellular Ca2+ influx.

### Claim 4 (depends on 3)

The islet-like organoid expressing monSTIM1 according to claim 3, wherein the intracellular Ca2+ influx can be reversibly regulated by light irradiation.

### Claim 5 (depends on 3)

The islet-like organoid expressing monSTIM1 according to claim 3, wherein the increase in intracellular Ca2+ influx promotes insulin secretion.

### Claim 6 (depends on 1)

The islet-like organoid expressing monSTIM1 according to claim 1, wherein the light irradiation is performed in cycles of irradiating light for 1 second and not irradiating light for 11 seconds.

### Claim 7 (depends on 1)

The islet-like organoid expressing monSTIM1 according to claim 1, wherein the islet-like organoid includes beta cells (0-cells) that cause an increase in intracellular Ca2+ influx by light irradiation.

### Claim 8

A preparation method of the islet-like organoid expressing monSTIM1 comprising the following steps:
1) a step of introducing monSTIM1 into stem cells;
2) a step of differentiating the monSTIM1-introduced stem cells of step 1) into definitive endoderm (DE) cells;
3) a step of differentiating the definitive endoderm cells of step 2) into pancreatic endoderm (PE) cells;
4) a step of differentiating the pancreatic endoderm cells of step 3) into endocrine progenitor (EP) cells;
5) a step of differentiating the endocrine progenitor cells of step 4) into hormone-expressing endocrine cells (EC); and
6) a step of differentiating the hormone-expressing endocrine cells of step 5) into an islet-like organoid (pancreatic islet-like organoid).

### Claim 9 (depends on 8)

The preparation method of the islet-like organoid expressing monSTIM1 according to claim 8, wherein the stem cells are embryonic stem cells, induced pluripotent stem cells, or adult stem cells.

### Claim 10 (depends on 9)

The preparation method of the islet-like organoid expressing monSTIM1 according to claim 9, wherein the induced pluripotent stem cells are generated from dermal fibroblasts of a neonatal diabetes patient.

### Claim 11 (depends on 8)

The preparation method of the islet-like organoid expressing monSTIM1 according to claim 8, wherein the monSTIM1 is introduced into the AAVS1 gene locus of stem cells.

### Claim 12 (depends on 8)

The preparation method of the islet-like organoid expressing monSTIM1 according to claim 8, wherein the monSTIM1 includes the nucleotide sequence represented by SEQ. ID. NO: 46.

### Claim 13 (depends on 8)

The preparation method of the islet-like organoid expressing monSTIM1 according to claim 8, wherein the stem cells into which the monSTIM1 has been introduced are homozygous clones.

### Claim 14 (depends on 8)

An islet-like organoid expressing monSTIM1 prepared by the method of claim 8.

### Claim 15 (depends on 14)

The islet-like organoid according to claim 14, wherein the islet-like organoid is for treating diabetes.

### Claim 16 (depends on 14)

The islet-like organoid according to claim 14, wherein the islet-like organoid is encapsulated with polycaprolactone.

### Claim 17 (depends on 16)

The islet-like organoid according to claim 16, wherein the encapsulated islet-like organoid causes human insulin secretion by light stimulation.
